Advertisement

Angiography in Pharmacologic Retinal Toxicity

  • Stephen G. Schwartz
  • William F. Mieler

Retinal angiography, specifically fluorescein angiography (FA), is important for the diagnosis and follow-up of pharmacologic retinal toxicity. At this time, there does not appear to be a significant role for indocyanine green (ICG) videoangiography, and even the role of optical coherence tomography (OCT) for these conditions is very limited. Fluorescein angiography appears to be particularly helpful in early cases of possible toxicity where the clinical findings may be mild. Early diagnosis is beneficial, as prompt discontinuation of the offending agent may on occasion reduce the risk of permanent vision loss.

Keywords

Optical Coherence Tomography Fluorescein Angiography Cystoid Macular Edema Color Photograph Retinal Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Cambiaggi A. Unusual ocular lesions in a case of systemic lupus erythematosus. Arch Ophthalmol 1957;57:451–453.Google Scholar
  2. 2.
    Hobbs HE, Sorsby A, Freedman A. Retinopathy following chloroquine therapy. Lancet 1959;2:478–480.PubMedCrossRefGoogle Scholar
  3. 3.
    Henkind P, Rothfield NE Ocular abnormalities in patients treated with synthetic antimalarial drugs. N Engl J Med 1963;269: 433–439.PubMedCrossRefGoogle Scholar
  4. 4.
    Okun E, Gouras P, Berstein H, von Sallman L. Chloroquine retinopathy. Arch Ophthalmol 1963;69:59–71.PubMedGoogle Scholar
  5. 5.
    Cruess AF, Schachat AP, Nicholl J, Augsburger JJ. Chloroquine retinopathy: is fluorescein angiography necessary? Ophthalmology 1985;92:1127–1129.PubMedGoogle Scholar
  6. 6.
    Easterbrook M. The use of Amsler grids in early chloroquine retinopathy. Ophthalmology 1984;91:1368–1372.PubMedGoogle Scholar
  7. 7.
    Hart WM, Burde RM, Johnston GP, Drews RC. Static perimetry in chloroquine retinopathy: perifoveal patterns of visual field depression. Arch Ophthalmol 1984;102:377–380.PubMedGoogle Scholar
  8. 8.
    Vu BLL, Easterbrook M, Hovis JK. Detection of color vision defects in chloroquine retinopathy. Ophthalmology 1999;106:1799–1804.PubMedCrossRefGoogle Scholar
  9. 9.
    Tzekov RT, Serrato A, Marmor MF. ERG findings in patients using hydroxychloroquine. Doc Ophthalmol 2004;108:87–97.PubMedCrossRefGoogle Scholar
  10. 10.
    Maturi RK, Yu M, Weleber RG. Multifocal electroretinographic evaluation of long-term hydroxychloroquine users. Arch Ophthalmol 2004;122:973–981.PubMedCrossRefGoogle Scholar
  11. 11.
    Rodriguez-Padilla JA, Hedges TR 3rd, Monson B, et al. High-speed ultra-high resolution optical coherence tomography findings in hydroxychloroquine retinopathy. Arch Ophthalmol 2007;125:775–780.PubMedCrossRefGoogle Scholar
  12. 12.
    Brinkley JR, Dubois EL, Ryan SJ. Long-term course of chloroquine retinopathy after cessation of medication. Am J Ophthalmol 1979;88:1–11.PubMedGoogle Scholar
  13. 13.
    Rubin M, Bernstein HN, Zvaifler NJ. Studies on the pharmacology of chloroquine. Arch Ophthalmol 1963;70:80–87.Google Scholar
  14. 14.
    Ehrenfeld M, Nesher R, Merin S. Delayed-onset chloroquine retinopathy. Br J Ophthalmol 1986;70:281–283.PubMedCrossRefGoogle Scholar
  15. 15.
    Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2002;109:1377–1382.PubMedCrossRefGoogle Scholar
  16. 16.
    American Academy of Ophthalmology. Comprehensive Adult Medical Eye Evaluation, Preferred Practice Pattern. San Francisco: American Academy of Ophthalmology, 2000.Google Scholar
  17. 17.
    Easterbrook M. Current concepts in monitoring patents on antimalarials. Aust N Z J Ophthalmol 1998;26:101–103.PubMedCrossRefGoogle Scholar
  18. 18.
    Brinton GS, Norton EWD, Zahn JR, Knighton RW. Ocular quinine toxicity. Am J Ophthalmol 1980;90:403–410.PubMedGoogle Scholar
  19. 19.
    Toxic maculopathy part II: a result of quinine usage as demonstrated by fluorescein angiography and electroretinography. Ann Ophthalmol 1975;7:1475–1481.Google Scholar
  20. 20.
    Bacon P, Spalton DJ, Smith SE. Blindness from quinine toxicity. Br J Ophthalmol 1988;72:219–224.PubMedCrossRefGoogle Scholar
  21. 21.
    Verdon W. Clinical electrophysiology in quinine induced retinal toxicity. Optom Vis Sci 2008;85:17–26.PubMedCrossRefGoogle Scholar
  22. 22.
    Weekley RD, Potts AM, Reboton J, May RH. Pigmentary retinopathy in patients receiving high doses of a new phenothiazine. Arch Ophthalmol 1960;64:65–76.PubMedGoogle Scholar
  23. 23.
    Meredith TA, Aaberg TM, Willerson D. Progressive chorioretinopathy after receiving thioridazine. Arch Ophthalmol 1978;96: 1172–1176.PubMedGoogle Scholar
  24. 24.
    Miller FS III, Bunt-Milam AH, Kalina RE. Clinical-ultrastructural study of thioridazine retinopathy. Ophthalmology 1982;89: 1478–1488.PubMedGoogle Scholar
  25. 25.
    Miyata M, Imai H, Ishikawa S, Nakajima S. Changes in human electroretinography associated with thioridazine administration. Ophthalmologica 1980;181:175–180.PubMedCrossRefGoogle Scholar
  26. 26.
    Marmor MF. Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function. Br J Ophthalmol 1990;74:739–742.PubMedCrossRefGoogle Scholar
  27. 27.
    Haimovici R, D’Amico DJ, Gragoudas ES, Sokol S, for the Deferoxamine Retinopathy Study Group. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmol 2002;109;164–171.Google Scholar
  28. 28.
    Mehta AM, Engstrom RE, Kreiger AE. Deferoxmaine-associated retinopathy after subcutaneous injection. Am J Ophthalmol 1994;118:260–262.PubMedGoogle Scholar
  29. 29.
    Rodriguez AS, Oterino JAM, Fernandez MAF. Unusual toxicity of deferoxamine. Ann Pharmacol 1999;33:505–506.CrossRefGoogle Scholar
  30. 30.
    Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from single “challenge” dose of deferoxamine. Clin Nephrol 1989;31:43–48.Google Scholar
  31. 31.
    Heier JS, Dragoo RA, Enzenauer RW, Waterhouse WJ. Screening for ocular toxicity in asymptomatic patients treated with tamoxifen. Am J Ophthalmol 1994;117:772–775.PubMedGoogle Scholar
  32. 32.
    Gorin MB, Day R, Constantino JP, et al. Long-term tamoxifen citrate use and potential ocular toxicity. Am J Ophthalmol 1998;125:493–501.PubMedCrossRefGoogle Scholar
  33. 33.
    Cortin P, Corriveau LA, Rousseau AP, et al. [Maculopathy with golden particles]. Can J Ophthalmol 1982;17:103–106.PubMedGoogle Scholar
  34. 34.
    Boudreault G, Cortin P, Corriveau LA, et al. [Canthaxanthine retinopathy: 1. Clinical study in 51 consumers]. Can J Ophthalmol 1983;18:325–328.PubMedGoogle Scholar
  35. 35.
    Weber U, Goerz G, Baseler H, Michaelis L. [Canthaxanthin retinopathy. Follow-up of over 6 years]. Klin Monatsbl Augenheilkd 1992;201:174–177.PubMedCrossRefGoogle Scholar
  36. 36.
    Stoelting RK, Miller RD. Basics of Anesthesia, 2nd ed. New York: Churchill Livingstone, 1989:64.Google Scholar
  37. 37.
    Bullock JD, Albert DM. Fleck retina. Appearance secondary to oxalate crystals from methoxyflurane anesthesia. Arch Ophthalmol 1975;93:26–31.PubMedGoogle Scholar
  38. 38.
    Novak MA, Roth AS, Levine MR. Calcium oxalate retinopathy associated with methoxyflurane abuse. Retina 1988;8:230–236.PubMedGoogle Scholar
  39. 39.
    Withering W. An Account of the Foxglove, and Some of Its Medical Uses: With Practical Remarks on Dropsy and Other Diseases. London: Robinson, 1785.Google Scholar
  40. 40.
    Weleber RG, Shults WT. Digoxin retinal toxicity. Clinical and electrophysiologic evaluation of a cone dysfunction syndrome. Arch Ophthalmol 1981;99:1568–1572.PubMedGoogle Scholar
  41. 41.
    Ballard SA, Gingell CJ, Tang K, et al. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998;159:2164–2171.PubMedCrossRefGoogle Scholar
  42. 42.
    Goldstein I, Lue TF, Padma-Nathan H, et al. Oral sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998;338: 1397–1404.PubMedCrossRefGoogle Scholar
  43. 43.
    Gabrieli CB, Regine F, Vingolo EM, Rispoli E, Fabbri A, Isidori A. Subjective visual halos after sildenafil (Viagra) administration: electroretinographic evaluation. Ophthalmology 2001;108:877–881.PubMedCrossRefGoogle Scholar
  44. 44.
    Tripathi A, O’Donnell NP. Branch retinal artery occlusion: another complication of sildenafil [letter]. Br J Ophthalmol 2000;84:928.CrossRefGoogle Scholar
  45. 45.
    Pomeranz HD, Smith KH, Hart WM Jr, Egan RA. Sildenafil-associated nonarteritic anterior ischemic optic neuropathy. Ophthalmology 2002;109(3):584–587.PubMedCrossRefGoogle Scholar
  46. 46.
    Sildenafil (Viagra) a cause of proliferative diabetic retinopathy? [letter] Eye 2000;14(5):785–786.Google Scholar
  47. 47.
    Allibhai ZA, Gale JS, Sheidow TS. Central serous chorioretinopathy in a patient taking sildenafil citrate. Ophthalmic Surg Lasers Imaging 2004;35:165–167.PubMedGoogle Scholar
  48. 48.
    Luu JK, Chappelow AV, McCulley TJ, Marmor ME. Acute effects of sildenafil on the electroretinogram and multifocal electroretinogram. Am J Ophthalmol 2001;132(3):388–394.PubMedCrossRefGoogle Scholar
  49. 49.
    Laties AM, Fraunfelder FT. Ocular safety of Viagra (sildenafil citrate). Trans Am Ophthalmol Soc 1999;97:115–125.PubMedGoogle Scholar
  50. 50.
    Marmor MF. Sildenafil (Viagra) and ophthalmology. Arch Ophthalmol 1999;117:518–519.PubMedGoogle Scholar
  51. 51.
    Hayreh MS, Hayreh SS, Baumbach GL, et al. Methyl alcohol poisoning. III. Ocular toxicity. Arch Ophthalmol 1977;95:1851–1858.PubMedGoogle Scholar
  52. 52.
    Ingemansson SO. Clinical observations on ten cases of methanol poisoning. Acta Ophthalmol 1984;62:15–24.Google Scholar
  53. 53.
    McKellar MJ, Hidajat RR, Elder MJ. Acute ocular methanol toxicity: clinical and electrophysiological features. Aust N Z J Ophthalmol 1997;25:225–230.PubMedCrossRefGoogle Scholar
  54. 54.
    McCuen BW II, Bessler M, Tano Y, Chandler D, Machemer R. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785–788.PubMedGoogle Scholar
  55. 55.
    Hida T, Chandler D, Arena JE, Machemer R. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190–195.PubMedGoogle Scholar
  56. 56.
    Pendergast SD, Eliott D, Machemer R. Retinal toxic effects following inadvertent intraocular injection of Celestone Soluspan. Arch Ophthalmol 1995;113:1230–1231.PubMedGoogle Scholar
  57. 57.
    McDonald HR, Schatz H, Allen AW, et al. Retinal toxicity secondary to intraocular gentamicin. Ophthalmology 1986;93:871–877.PubMedGoogle Scholar
  58. 58.
    Campochiaro PA, Conway BP. Aminoglycoside toxicity—a survey of retinal specialists: implications for ocular use. Arch Ophthalmol 1991;109:946–950.PubMedGoogle Scholar
  59. 59.
    D’Amico DJ, Caspers-Velu L, Libert J, et al. Comparative toxicity of intravitreal aminoglycoside antibiotics. Am J Ophthalmol 1985;100:264–275.PubMedGoogle Scholar
  60. 60.
    Seawright AA, Bourke RD, Cooling RJ. Macula toxicity after intravitreal amikacin. Aust N Z J Ophthalmol 1996;24:143–146.PubMedCrossRefGoogle Scholar
  61. 61.
    Tse DT, Ober RR. Talc retinopathy. Am J Ophthalmol 1980;90: 624–640.PubMedGoogle Scholar
  62. 62.
    AtLee WE. Talc and cornstarch emboli in eyes of drug users. JAMA 1972;219:49.PubMedCrossRefGoogle Scholar
  63. 63.
    Martidis A, Yung CW, Ciulla TA. Talc embolism: a static retinopathy. Am J Ophthalmol 1997;124:841–843.PubMedGoogle Scholar
  64. 64.
    Friberg TR, Gragoudas ES, Regan CDJ. Talc emboli and macular ischemia in intravenous drug abuse. Arch Ophthalmol 1979;97:1089.PubMedGoogle Scholar
  65. 65.
    Kresca LJ, Goldberg MF, Jampol LM. Talc emboli and retinal neovascularization in a drug abuser. Am J Ophthalmol 1979;87:334.PubMedGoogle Scholar
  66. 66.
    Brucker AJ. Disc and peripheral neovascularization secondary to talc and cornstarch emboli. Am J Ophthalmol 1979;88:864.PubMedGoogle Scholar
  67. 67.
    Gombos GM, Moreno DH, Bedrossian PB. Retinal vascular occlusion induced by oral contraceptives. Ann Ophthalmol 1975;7:215–217.PubMedGoogle Scholar
  68. 68.
    Perry HD, Mallen FJ. Cilioretinal artery occlusion associated with oral contraceptives. Am J Ophthalmol 1977;84:56–58.PubMedGoogle Scholar
  69. 69.
    Stowe GC, Jakov AN, Albert DM. Central retinal vascular occlusion associated with oral contraceptives. Am J Ophthalmol 1978;86:798–801.PubMedGoogle Scholar
  70. 70.
    Petersson GJ, Fraunfelder FT, Meyer SM. Oral contraceptives. Ophthalmol 1981;88:368–371.Google Scholar
  71. 71.
    Garg SK, Chase P, Marshall G, et al. Oral contraceptives and renal and retinal complications in young women with insulindependent diabetes mellitus. JAMA 1994;271:1099–1102.PubMedCrossRefGoogle Scholar
  72. 72.
    Guyer DR, Tiedeman J, Yannuzzi LA, et al. Interferon-associated retinopathy. Arch Ophthalmol 1993;111:350–356.PubMedGoogle Scholar
  73. 73.
    Nadir A, Amin A, Chalisa N, et al. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat 2000;7(6):466–470.PubMedCrossRefGoogle Scholar
  74. 74.
    Tokai R, Ikeda T, Miyaura T, et al. Interferon-associated retinopathy and cystoid macular edema. Arch Ophthalmol 2001;119(7): 1077–1079.PubMedGoogle Scholar
  75. 75.
    Willson RL, Ross RD, Willson LM, et al. Interferon-associated retinopathy in a young, insulin-dependent diabetic patient. Retina 2000;20:413–415.PubMedGoogle Scholar
  76. 76.
    Thomas JV, Gragoudas ES, Blair NP, Lapus JV. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol 1978;96:625–628.PubMedGoogle Scholar
  77. 77.
    Mehelas TJ, Kollarits CR, Martin WG. Cystoid macular edema presumably induced by dipivefrin hydrochloride (Propine). Am J Ophthalmol 1984;94:682.Google Scholar
  78. 78.
    Hoyng PFJ, Rulo AH, Greve EL, Astin M, Gjotterberg M. Fluorescein angiographic evaluation of the effect of latanoprost treatment on blood-retinal barrier integrity: a review of studies conducted on pseudophakic glaucoma patients and on phakic and aphakic monkeys. Surv Ophthalmol 1997;41(suppl 2): S83–S88.PubMedCrossRefGoogle Scholar
  79. 79.
    Heier JS, Steinert RF, Frederick AR Jr. Cystoid macular edema associated with latanoprost use. Arch Ophthalmol 1998;116: 680–682.PubMedGoogle Scholar
  80. 80.
    Moroi SE, Gottfredsdottir MS, Schteingart MT, et al. Cystoid macular edema associated with latanoprost therapy in a case series of patients with glaucoma and ocular hypertension. Ophthalmology 1999;106:1024–1029.PubMedCrossRefGoogle Scholar
  81. 81.
    Wand M, Gaudio AR, Shields MB. Latanoprost and cystoid macular edema in high-risk aphakic or pseudophakic eyes. J Cataract Refract Surg 2001;27(9): 1397–1401.PubMedCrossRefGoogle Scholar
  82. 82.
    Gass JDM. Nicotinic acid maculopathy. Am J Ophthalmol 1973;76:500–510.PubMedGoogle Scholar
  83. 83.
    Millay RH, Klein ML, Illingworth DR. Niacin maculopathy. Ophthalmology 1988;95:930–936.PubMedGoogle Scholar
  84. 84.
    Dajani HM, Lauer AK. Optical coherence tomography findings in niacin maculopathy. Can J Ophthalmol 2006;41(2): 197–200.PubMedCrossRefGoogle Scholar
  85. 85.
    Jampol LM. Niacin maculopathy. Ophthalmology 1988;95: 1704–1705.PubMedGoogle Scholar
  86. 86.
    O’Brien DM, Farmer SG, Kalina RE, Leon JA. Acute macular neuroretinopathy following intravenous sympathomimetics. Retina 1989;9:281–286.PubMedGoogle Scholar
  87. 87.
    Desai UR, Sudhamathi K, Natarajan S. Intravenous epinephrine and acute macular neuroretinopathy. Arch Ophthalmol 1993;111:1026–1027.PubMedGoogle Scholar
  88. 88.
    Maddalena MA. Transient myopia associated with acute glaucoma and retinal edema: following vaginal administration of sulfanilamide. Arch Ophthalmol 1968;80:186–188.PubMedGoogle Scholar
  89. 89.
    Ryan EH, Jampol LM. Drug-induced acute transient myopia with retinal folds. Retina 1986;6:220–223.PubMedCrossRefGoogle Scholar
  90. 90.
    Grinbaum A, Ashkenazi I, Avni I, Blumenthal M. Transient myopia following metronidazole treatment for trichomonas vaginalis. JAMA 1992;267:511–512.PubMedCrossRefGoogle Scholar
  91. 91.
    Soylev MF, Green RL, Feldon SE. Choroidal effusion as a mechanism for transient myopia induced by hydrochlorothiazide and triamterene. Am J Ophthalmol 1995;120:395–397.PubMedGoogle Scholar
  92. 92.
    Banta JT, Hoffman K, Budenz DL, Ceballos E, Greenfield DS. Presumed topiramate-induced bilateral acute angle-closure glaucoma. Am J Ophthalmol 2001;132:112–114.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Stephen G. Schwartz
    • 1
  • William F. Mieler
    • 2
  1. 1.Bascom Palmer Eye InstituteUniversity of Miami Miller School of MedicineNaples
  2. 2.Department of Ophthalmology & Visual ScienceUniversity of ChicagoChicago

Personalised recommendations